Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Despite the influx of money, the Florida Standard collapsed in early 2024, soon after DeSantis exited the presidential race.